The national drug regulator on January 3 gave “emergency restricted” approval to two vaccine candidates – Covaxin, developed by Bharat Biotech, and Covishield, a version of the Oxford-AstraZeneca’s vaccine that is being manufactured under licence by the Serum Institute of India.